Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
UMC Utrecht
National Cancer Institute (NCI)
Kyoto University Hospital
Peking University First Hospital
Abramson Cancer Center at Penn Medicine
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
European Organisation for Research and Treatment of Cancer - EORTC
University of Erlangen-Nürnberg Medical School
Mayo Clinic
Sohag University
UNICANCER
Radiation Therapy Oncology Group
Institute of Cancer Research, United Kingdom
Radiation Therapy Oncology Group
University of California, San Francisco
Trans Tasman Radiation Oncology Group
Alliance for Clinical Trials in Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Spanish Oncology Genito-Urinary Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
National Cancer Institute (NCI)
SWOG Cancer Research Network
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Eli Lilly and Company